Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat with FND for Relapsed/Refractory Mantle Cell Lymphoma
NCT01578343Phase 2Terminated
- Sponsor
- Samsung Medical Center
- Start
- Jun 2012
- Primary completion
- Sep 2015
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in mantle cell lymphoma (MCL), sponsored by Samsung Medical Center. Primary endpoint: Response rate of vorinostat/FND at 16 weeks. Started Jun 2012; status: terminated.
02
Drugs
vorinostat
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01578343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01578343.